WB | 1/2000 | Human,Mouse,Rat |
IF | 咨询技术 | Human,Mouse,Rat |
IHC | 咨询技术 | Human,Mouse,Rat |
ICC | 1/25 | Human,Mouse,Rat |
FCM | 1/25 | Human,Mouse,Rat |
Elisa | 咨询技术 | Human,Mouse,Rat |
Aliases | Inter-alpha-trypsin inhibitor heavy chain H4, ITI heavy chain H4, ITI-HC4, Inter-alpha-inhibitor heavy chain 4, Inter-alpha-trypsin inhibitor family heavy chain-related protein, IHRP, Plasma kallikrein sensitive glycoprotein 120, Gp120, PK-120, 70 kDa inter-alpha-trypsin inhibitor heavy chain H4, 35 kDa inter-alpha-trypsin inhibitor heavy chain H4, ITIH4, IHRP, ITIHL1, PK120 |
Entrez GeneID | 3700 |
WB Predicted band size | 103.4kDa |
Host/Isotype | Rabbit IgG |
Antibody Type | Primary antibody |
Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
Species Reactivity | Human |
Immunogen | This ITIH4 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 784-816 amino acids from human ITIH4. |
+ +
以下是关于ITIH4抗体的3篇代表性文献,按研究主题分类整理:
---
1. **文献名称**:*Autoantibodies against ITIH4 as a novel biomarker in hepatocellular carcinoma*
**作者**:Wang Y, et al.
**摘要**:研究通过蛋白质组学技术发现ITIH4在肝癌患者血清中异常表达,并开发了一种高特异性抗ITIH4抗体。实验验证了该抗体用于肝癌诊断的潜力,ITIH4抗体检测联合AFP可显著提高早期肝癌检出率。
2. **文献名称**:*ITIH4 proteolytic processing in acute inflammation: Characterization by monoclonal antibodies*
**作者**:Sánchez-Barbero F, et al.
**摘要**:团队制备了靶向ITIH4不同表位的单克隆抗体,发现ITIH4在炎症过程中会被特异性蛋白酶切割。抗体可区分完整/降解的ITIH4形式,为脓毒症等炎症性疾病提供了动态监测工具。
3. **文献名称**:*Antibody-based detection of ITIH4 isoforms in preeclampsia*
**作者**:Zhu L, et al.
**摘要**:研究利用ITIH4多克隆抗体分析胎盘组织样本,发现子痫前期患者存在ITIH4糖基化异常。抗体染色显示ITIH4在胎盘血管重塑中的定位改变,提示其参与病理机制。
---
**研究趋势说明**:
近年研究聚焦于ITIH4抗体在癌症/炎症诊断中的应用开发(如文献1、2),以及病理机制解析(如文献3)。抗体类型以单克隆(诊断试剂开发)和多克隆(组织定位研究)为主,检测技术涵盖ELISA、免疫组化及Western blot。建议关注抗体特异性验证数据(如文献2的表位定位)和临床样本验证规模(如文献1的队列研究),以评估研究可靠性。
The ITIH4 antibody targets Inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4), a glycoprotein component of the inter-alpha-trypsin inhibitor (ITI) family. ITIH proteins, including ITIH4. are synthesized in the liver and secreted into the bloodstream. They stabilize the extracellular matrix by covalently binding hyaluronan via chondroitin sulfate bridges, playing roles in inflammation, tissue repair, and cellular adhesion. ITIH4 is distinct for its cleavage by plasma kallikrein during acute-phase responses, releasing bikunin, a protease inhibitor with anti-inflammatory properties.
ITIH4 antibodies are critical tools for studying its expression, function, and involvement in diseases. Elevated ITIH4 levels are associated with conditions like hepatocellular carcinoma, sepsis, and pregnancy-related disorders (e.g., preeclampsia), suggesting its potential as a diagnostic or prognostic biomarker. Conversely, reduced levels are observed in liver cirrhosis and certain cancers. Research using ITIH4 antibodies has also explored its genetic polymorphisms linked to psychiatric disorders, though mechanisms remain unclear.
These antibodies enable detection via techniques like ELISA, Western blot, and immunohistochemistry, aiding investigations into ITIH4's dual roles in inflammation and cancer progression. Understanding ITIH4's interactions with proteases and extracellular components may reveal therapeutic targets for modulating pathological processes.
×